Advertisement
EXEL vs GMAB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and GMAB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 1 FA rating(s) are green whileGMAB’s FA Score has 1 green FA rating(s).
- EXEL’s FA Score: 1 green, 4 red.
- GMAB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 2 TA indicator(s) are bullish while GMAB’s TA Score has 5 bullish TA indicator(s).
- EXEL’s TA Score: 2 bullish, 6 bearish.
- GMAB’s TA Score: 5 bullish, 5 bearish.
Price Growth
EXEL (@Biotechnology) experienced а -0.05% price change this week, while GMAB (@Biotechnology) price change was +0.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.93%. For the same industry, the average monthly price growth was -1.71%, and the average quarterly price growth was +1913.57%.
Reported Earning Dates
EXEL is expected to report earnings on Aug 05, 2026.
GMAB is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Biotechnology (-1.93% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| EXEL | GMAB | EXEL / GMAB | |
| Capitalization | 14B | 17.9B | 78% |
| EBITDA | 986M | 1.29B | 77% |
| Gain YTD | 26.968 | -5.292 | -510% |
| P/E Ratio | 18.43 | 22.18 | 83% |
| Revenue | 2.38B | 3.9B | 61% |
| Total Cash | 777M | 1.52B | 51% |
| Total Debt | 170M | 5.35B | 3% |
EXEL | GMAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 13 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 41 | 47 | |
P/E GROWTH RATING 1..100 | 60 | 12 | |
SEASONALITY SCORE 1..100 | 11 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EXEL's Valuation (80) in the Biotechnology industry is in the same range as GMAB (80) in the null industry. This means that EXEL’s stock grew similarly to GMAB’s over the last 12 months.
EXEL's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for GMAB (100) in the null industry. This means that EXEL’s stock grew significantly faster than GMAB’s over the last 12 months.
EXEL's SMR Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that EXEL’s stock grew similarly to GMAB’s over the last 12 months.
EXEL's Price Growth Rating (41) in the Biotechnology industry is in the same range as GMAB (47) in the null industry. This means that EXEL’s stock grew similarly to GMAB’s over the last 12 months.
GMAB's P/E Growth Rating (12) in the null industry is somewhat better than the same rating for EXEL (60) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than EXEL’s over the last 12 months.
| EXEL | GMAB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 55% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 59% |
| Advances ODDS (%) | 7 days ago 67% | 2 days ago 62% |
| Declines ODDS (%) | 9 days ago 58% | 4 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 64% |
Advertisement